Citius Oncology Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022
Revenue	5.61	-	-	-	-
Cost of Revenue	1.12	-	-	-	-
Gross Profit	4.49	-	-	-	-
Selling, General & Admin	41.61	17.1	15.65	7.88	0.14
Depreciation & Amortization Expenses	2.29	-	-	-	-
Research & Development	4.11	6.42	4.93	4.24	-
Total Operating Expenses	48.02	23.52	20.57	12.12	0.14
Operating Income	-43.52	-23.52	-20.57	-12.12	-0.14
Interest Income	-	0.04	-	-	0.49
Interest Expense	0.3	0.22	-	-	-
Other Non-Operating Income (Expense)	1.76	-	-	-	0.03
Total Non-Operating Income (Expense)	2.06	-0.18	-	-	0.52
Pretax Income	-41.95	-23.7	-20.57	-12.12	0.38
Provision for Income Taxes	0.56	1.06	0.58	0.58	-
Net Income	-42.51	-24.76	-21.15	-12.7	0.38
Net Income to Common	-42.51	-24.76	-21.15	-12.7	0.38
Shares Outstanding (Basic)	84	73	68	2	2
Shares Outstanding (Diluted)	84	73	68	2	2
Shares Change (YoY)	20.38%	7.66%	2798.38%	25.86%	-
EPS (Basic)	-0.47	-0.34	-0.31	-0.19	0.12
EPS (Diluted)	-0.47	-0.34	-0.31	-0.19	0.12
Free Cash Flow	-16.68	-5.49	0.13	0	-0.05
Free Cash Flow Per Share	-0.20	-0.07	0.00	-	-0.03
Gross Margin	80.07%	-	-	-	-
Operating Margin	-775.61%	-	-	-	-
Profit Margin	-757.57%	-	-	-	-
FCF Margin	-297.23%	-	-	-	-
EBITDA	-41.23	-23.52	-20.57	-12.12	-0.14
EBITDA Margin	-734.73%	-	-	-	-
EBIT	-43.52	-23.52	-20.57	-12.12	-0.14
EBIT Margin	-775.61%	-	-	-	-
Effective Tax Rate	-1.34%	-4.46%	-2.80%	-4.75%	0.00%

SEC Filings: 10-K · 10-Q